Human Anti-CD3 x Anti-CD44 Bispecific Antibody (IgG-IgG) (BSIG-H242)

Anti-CD3 x Anti-CD44 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-CD44 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & CD44

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Glioblastoma; Squamous cancer

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

CD44

Gene ID

960

UniProt ID

P16070

Alternative Names

CD44; CD44 antigen; ECMRIII; Extracellular matrix receptor III; HCAM; Homing cell adhesion molecule; Pgp-1; phagocytic glycoprotein-1; HUTCH-1; Ly-24; Pgp-1; HERMES; AU023126; AW121933; AW146109

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human Anti-CD3 x Anti-CD44 Bispecific Antibody (IgG-IgG) (BSIG-H242). Click the button below to contact us or submit your feedback about this product.

Human Anti-CD3 x Anti-CD44 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-H242)

Specifications

Targets

Customer Reviews and Q&As